AstraZeneca PLC (XBUL:ZEG) Stock Price, Trades & News

AstraZeneca is a global biopharmaceutical company formed by the 1999 merger of Sweden's Astra and the UK's Zeneca, headquartered in Cambridge, England. Oncology is its largest franchise, led by Tagrisso for lung cancer, Imfinzi immunotherapy, and the antibody-drug conjugate Enhertu partnered with Daiichi Sankyo, alongside Lynparza and Calquence. Its biopharmaceuticals business spans cardiovascular, renal, and metabolic medicines, including diabetes therapy Farxiga, and respiratory and immunology products such as Symbicort, Fasenra, and Saphnelo. The rare disease unit, built on the 2021 acquisition of Alexion, contributes complement-inhibitor therapies Soliris and Ultomiris. AstraZeneca sells in over 100 countries, with the United States its largest market and substantial emerging markets exposure including China. Its ADSs trade on NASDAQ.

Financial Strength

6/10

Name	Current	Vs Industry
Cash-To-Debt	0.15
Equity-to-Asset	0.43
Debt-to-Equity	0.64
Debt-to-EBITDA	1.58
Interest Coverage	8
Piotroski F-Score	8/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	3.27	Distress Grey Safe
Beneish M-Score	-2.56	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

8/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	6.4
	3-Year EBITDA Growth Rate	25
	3-Year EPS without NRI Growth Rate	32.3
	3-Year FCF Growth Rate	2.9
	3-Year Book Growth Rate	6.1
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	10.91
	Future 3-5Y Total Revenue Growth Rate Estimate	6.56

Momentum Rank

5/10

	Name	Current	Vs Industry		Vs History
	9-Day RSI	1.7
	14-Day RSI	9.79
	6-1 Month Momentum %	-7.96
	12-1 Month Momentum %	14.22

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	0.89
	Quick Ratio	0.67
	Cash Ratio	0.16
	Days Inventory	216.9
	Days Sales Outstanding	79.69
	Days Payable	642.73

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Dividend Growth Rate	0.2
	Shareholder Yield %	2.39

Profitability Rank

7/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	81.88
	Operating Margin %	22.77
	Net Margin %	17.03
	EBITDA Margin %	33.32
	FCF Margin %	17.48
	OCF Margin %	22.37
	ROE %	22.1
	ROA %	9.18
	ROIC %	12.1
	3-Year ROIIC %	126.32
	ROC (Joel Greenblatt) %	98.44
	ROCE %	17.59
	Years of Profitability over Past 10-Year	10
	Moat Score	7
	Tariff Resilience Score	9

GF Value Rank

9/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	23.43
	Forward PE Ratio	15.94
	PE Ratio without NRI	23.43
	Shiller PE Ratio	42.59
	Price-to-Owner-Earnings	23.23
	PEG Ratio	1.04
	PS Ratio	3.99
	PB Ratio	4.81
	Price-to-Free-Cash-Flow	40.65
	Price-to-Operating-Cash-Flow	17.89
	EV-to-EBIT	20.03
	EV-to-Forward-EBIT	15.07
	EV-to-EBITDA	14.04
	EV-to-Forward-EBITDA	12.63
	EV-to-Revenue	4.67
	EV-to-Forward-Revenue	4.43
	EV-to-FCF	44.89
	Price-to-GF-Value	0.87
	Price-to-Projected-FCF	2.14
	Price-to-Median-PS-Value	0.85
	Price-to-Peter-Lynch-Fair-Value	0.94
	Earnings Yield (Greenblatt) %	4.99
	FCF Yield %	2.32
	Forward Rate of Return (Yacktman) %	22.74

Financials (Next Earnings Date:2026-11-06 Est.)

Annual Quarterly TTM

XBUL:ZEG's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

AstraZeneca PLC Executives

Details

GF Value™: €180.71

XBUL:ZEG

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 1 Medium warning sign with ZEG. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	52,617.163
	EPS (TTM) (€)	5.736
	Beta	-
	3-Year Sharpe Ratio	-
	3-Year Sortino Ratio	-
	Volatility %	29.65
	14-Day RSI	9.79
	14-Day ATR (€)	0.001358
	20-Day SMA (€)	157.8
	12-1 Month Momentum %	14.22
	52-Week Range (€)	137.8 - 174.3
	Shares Outstanding (Mil)	1,550.9

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	8
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

AstraZeneca PLC Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

AstraZeneca PLC Stock Events

Financials Calendars

Event	Date	Price (€)
Annual report for 2026	2027-02-24	In 155 days
Fourth quarter earnings conference call for 2026	2027-02-10 11:45	In 142 days
Fourth quarter earnings results for 2026	2027-02-10 07:00	In 142 days
Third quarter earnings conference call for 2026	2026-11-06 13:00	In 46 days
Third quarter earnings results for 2026	2026-11-06	In 45 days
Guidance call for 2026	2026-09-08 11:00	139.90 (+0.00%)
GBP 0.795000 Cash Dividend	2026-08-06	140.75 (+0.00%)
Second quarter earnings conference call for 2026	2026-07-27 10:45	148.90 (+0.00%)
Second quarter earnings results for 2026	2026-07-27	148.90 (+0.00%)
Conference, J.P. Morgan European Healthcare Forum	2026-06-18	153.95 (+0.00%)

Show

Entries

AstraZeneca PLC Frequently Asked Questions

What is AstraZeneca PLC(XBUL:ZEG)'s stock price today?

The current price of XBUL:ZEG is €157.80. The 52 week high of XBUL:ZEG is €174.30 and 52 week low is €137.80.

When is next earnings date of AstraZeneca PLC(XBUL:ZEG)?

The next earnings date of AstraZeneca PLC(XBUL:ZEG) is 2026-11-06 Est..

Does AstraZeneca PLC(XBUL:ZEG) pay dividends? If so, how much?

AstraZeneca PLC(XBUL:ZEG) does not pay dividend.

Press Release

	Subject	Date
	ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTIN	2026-09-13
	TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial	2026-09-13
	IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stag	2026-09-08
	Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials	2026-09-08
	ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer	2026-09-04
	AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancer	2026-09-01
	TEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints	2026-08-27
	ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cel	2026-08-17
	TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer a	2026-08-17
	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN	2026-08-06

10/Page

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by FactSet. Analyst estimates data is sourced from both Refinitiv and FactSet, with priority given to Refinitiv data. Data is updated daily.